We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wright Medical Group (WMGI) Q2 Loss Narrower than Expected
Read MoreHide Full Article
Wright Medical Group N.V. reported adjusted loss of 7 cents per share in the second quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 9 cents.
Also, loss narrowed by 2 cents on a year-over-year basis.
Net sales in the second quarter totaled $179.7 million, which surpassed the consensus mark of $178 million.
Meanwhile, in three of the last four quarters, the company delivered positive earnings surprises, the average being 15.04%. Currently, the stock has a Zacks Rank #3 (Hold).
Quarter in Detail
Wright Medical currently reports revenues under the Total Extremities & Biologics segment.
Consolidated sales at the segment in the U.S. increased 9.1% from the year-ago quarter to almost $132.9 million. Internationally, sales in the extremities and biologics business were down 4.3% year over year to $46.8 million.
Wright Medical Group N.V. Price, Consensus and EPS Surprise
Total Extremities & Biologics includes four sub-segments, namely, Lower Extremities, Upper Extremities, Biologics and Sports Med & Other.
Lower Extremities: Sales at the segment increased 1.3% on a year-over-year basis to $69.1 million in the quarter.
The U.S. lower extremities business sales increased 4.5% in the second quarter. Per management, growth in the U.S. lower extremities was driven by total ankle growth rates and reduced headwinds from dis-synergies resulted in a 4.5 percentage point improvement from the first quarter growth rate.
Internationally, lower extremities sales fell 9.1% on a year-over-year basis.
Upper Extremities: Sales at the segment increased 9% on a year-over-year basis to $80.5 million in the quarter under review.
The U.S. upper extremities business grew 15.3% on a year-over-year basis, driven by the ongoing launch of the PERFORM Reversed glenoid along with the expanded BLUEPRINT surgical planning modules that became available during the quarter.
However, Upper extremities sales decreased 4% on a year-over-year basis internationally.
Biologics: Sales at the segment rose 7.7% on a year-over-year basis to $24.4 million in the quarter.
The U.S. biologics business grew 8.3% to $19.3 million in the quarter. Per management, AUGMENT had an impressive quarter with improvement in average daily revenue when compared to the first quarter, whereas the core biologics portfolio continued to be challenging. Management expects growth in the U.S. biologics business in the second half of 2017 through both the sales force expansion initiative in lower extremities and cross-selling programs of core biologic products with the upper extremities sales force.
Sales at the segment grew 5.4% internationally on a year-over-year basis.
Sports Med & Other: Sales at the segment dropped 5.1% to $5.7 million from the year-ago quarter.
The U.S. sports med & other segment sales declined 17.7% to $1.8 million and increased 2.1% internationally in the second quarter.
Margin Details
Adjusted gross margin, as a percentage of revenues, is pegged at 78.8% for the quarter, expansion of roughly 30 basis points (bps) on a year-over-year basis.
Selling, general and administrative expenses accounted for 71.1% of total revenues in the second quarter, totaling $130.8 million, a contraction of 280 bps from the year-ago quarter.
Notably, expenses on Research and Development (R&D) were $12.5 million in the second quarter, up 3.6% on a year-over-year basis.
Guidance
Wright Medical reiterated its full-year guidance.
The company continues to expect net sales for full-year 2017 in the band of $755 million to $765 million, representing growth of 9% to 11%. This includes a negative impact from foreign currency exchange of approximately 1%. Notably, the midpoint of the net sales guidance represents constant currency growth of approximately 13%.
The company forecasts full-year 2017 adjusted EBITDA from continuing operations in the range of $78.5 million to $85.5 million.
Our Take
Wright Medical exited the second quarter on an impressive note with both revenues and earnings beating the Zacks Consensus Estimate. Also, strong margin and reiterated full-year outlook buoys optimism. The company is putting efforts in product innovation through research and development. Wright Medical launched INVISION Total Ankle Revision System in July. This is the first system developed for total ankle revision arthroplasty. Per management, PERFORM Reversed launch will boost revenues in the later half of the year after the company delivers additional instrument sets to the U.S. field.
However, decrease in both Lower extremities sales and Upper extremities sales internationally is a matter of concern.
Key Picks
A few better-ranked medical stocks are Edwards Lifesciences Corporation (EW - Free Report) , INSYS Therapeutics, Inc. and Align Technology, Inc. (ALGN - Free Report) . Notably, Edwards Lifesciences INSYS Therapeutics and Align Technology sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
INSYS Therapeutics has a long-term expected earnings growth rate of 20%. The stock posted a stellar four quarter average earnings surprise of 37.8%.
Align Technology has an expected long-term adjusted earnings growth of almost 26.6%. The stock has added roughly 23.5% over the last three months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 5.3% over the last three months.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Wright Medical Group (WMGI) Q2 Loss Narrower than Expected
Wright Medical Group N.V. reported adjusted loss of 7 cents per share in the second quarter of 2017, narrower than the Zacks Consensus Estimate of a loss of 9 cents.
Also, loss narrowed by 2 cents on a year-over-year basis.
Net sales in the second quarter totaled $179.7 million, which surpassed the consensus mark of $178 million.
Meanwhile, in three of the last four quarters, the company delivered positive earnings surprises, the average being 15.04%. Currently, the stock has a Zacks Rank #3 (Hold).
Quarter in Detail
Wright Medical currently reports revenues under the Total Extremities & Biologics segment.
Consolidated sales at the segment in the U.S. increased 9.1% from the year-ago quarter to almost $132.9 million. Internationally, sales in the extremities and biologics business were down 4.3% year over year to $46.8 million.
Wright Medical Group N.V. Price, Consensus and EPS Surprise
Wright Medical Group N.V. Price, Consensus and EPS Surprise | Wright Medical Group N.V. Quote
Total Extremities & Biologics includes four sub-segments, namely, Lower Extremities, Upper Extremities, Biologics and Sports Med & Other.
Lower Extremities: Sales at the segment increased 1.3% on a year-over-year basis to $69.1 million in the quarter.
The U.S. lower extremities business sales increased 4.5% in the second quarter. Per management, growth in the U.S. lower extremities was driven by total ankle growth rates and reduced headwinds from dis-synergies resulted in a 4.5 percentage point improvement from the first quarter growth rate.
Internationally, lower extremities sales fell 9.1% on a year-over-year basis.
Upper Extremities: Sales at the segment increased 9% on a year-over-year basis to $80.5 million in the quarter under review.
The U.S. upper extremities business grew 15.3% on a year-over-year basis, driven by the ongoing launch of the PERFORM Reversed glenoid along with the expanded BLUEPRINT surgical planning modules that became available during the quarter.
However, Upper extremities sales decreased 4% on a year-over-year basis internationally.
Biologics: Sales at the segment rose 7.7% on a year-over-year basis to $24.4 million in the quarter.
The U.S. biologics business grew 8.3% to $19.3 million in the quarter. Per management, AUGMENT had an impressive quarter with improvement in average daily revenue when compared to the first quarter, whereas the core biologics portfolio continued to be challenging. Management expects growth in the U.S. biologics business in the second half of 2017 through both the sales force expansion initiative in lower extremities and cross-selling programs of core biologic products with the upper extremities sales force.
Sales at the segment grew 5.4% internationally on a year-over-year basis.
Sports Med & Other: Sales at the segment dropped 5.1% to $5.7 million from the year-ago quarter.
The U.S. sports med & other segment sales declined 17.7% to $1.8 million and increased 2.1% internationally in the second quarter.
Margin Details
Adjusted gross margin, as a percentage of revenues, is pegged at 78.8% for the quarter, expansion of roughly 30 basis points (bps) on a year-over-year basis.
Selling, general and administrative expenses accounted for 71.1% of total revenues in the second quarter, totaling $130.8 million, a contraction of 280 bps from the year-ago quarter.
Notably, expenses on Research and Development (R&D) were $12.5 million in the second quarter, up 3.6% on a year-over-year basis.
Guidance
Wright Medical reiterated its full-year guidance.
The company continues to expect net sales for full-year 2017 in the band of $755 million to $765 million, representing growth of 9% to 11%. This includes a negative impact from foreign currency exchange of approximately 1%. Notably, the midpoint of the net sales guidance represents constant currency growth of approximately 13%.
The company forecasts full-year 2017 adjusted EBITDA from continuing operations in the range of $78.5 million to $85.5 million.
Our Take
Wright Medical exited the second quarter on an impressive note with both revenues and earnings beating the Zacks Consensus Estimate. Also, strong margin and reiterated full-year outlook buoys optimism. The company is putting efforts in product innovation through research and development. Wright Medical launched INVISION Total Ankle Revision System in July. This is the first system developed for total ankle revision arthroplasty. Per management, PERFORM Reversed launch will boost revenues in the later half of the year after the company delivers additional instrument sets to the U.S. field.
However, decrease in both Lower extremities sales and Upper extremities sales internationally is a matter of concern.
Key Picks
A few better-ranked medical stocks are Edwards Lifesciences Corporation (EW - Free Report) , INSYS Therapeutics, Inc. and Align Technology, Inc. (ALGN - Free Report) . Notably, Edwards Lifesciences INSYS Therapeutics and Align Technology sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
INSYS Therapeutics has a long-term expected earnings growth rate of 20%. The stock posted a stellar four quarter average earnings surprise of 37.8%.
Align Technology has an expected long-term adjusted earnings growth of almost 26.6%. The stock has added roughly 23.5% over the last three months.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 5.3% over the last three months.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>